Precigen ActoBio

Precigen ActoBio is a clinical-stage biotechnology company pioneering a proprietary class of microbe-based biopharmaceuticals known as ActoBiotics. The company's platform utilizes genetically modified food-grade bacteria, specifically Lactococcus lactis, to deliver therapeutic proteins and peptides directly to mucosal tissues such as the gastrointestinal tract or oral cavity. This localized delivery approach is designed to improve therapeutic outcomes while reducing systemic exposure and potential side effects. ActoBio's pipeline includes candidates for Type 1 diabetes, oral mucositis, and celiac disease. As a subsidiary of Precigen, the company integrates synthetic biology with microbiology to develop innovative treatments for autoimmune and inflammatory disorders.